MLTG Fall Registry Software Vendor Webinar

V27 Implementation

NAACCR

1

Agenda

- Welcome from MLTG Co-Chairs
  - Serban Negoita-
  - Manxia Wu
- Implementation Guidelines and Conversion Specs
  - Jim Hofferkamp/ Michelle Esterly
- AJCC Cancer Surveillance DLL
  - Daniel Oluwadare
- SEER Staging API
  - Nicola Schussler
- Cancer PathCHART Update
  - Alison Van Dyke
- Q&A
- NAACCR Edits Metafile
  - Jim Hofferkamp
- V27 Updates (SSDI WG Group)
- V27 Changes (AJCC)
  - Donna Gress
- V27 Changes (NCDB)
  - Claudia Byrd
- V27 Changes (NAACCR and Other Sponsors)
  - Jim Hofferkamp
- Q&A

NAACCR

2

Welcome!

During this session, representatives from the standard setters will present updates on changes approved for 2027 (v27) implementation.

Vendors will also have the opportunity to ask questions and provide feedback directly to the standard setters.

NAACCR

3

Implementation Guidelines and Conversion Specifications

Jim Hofferkamp

Michelle Esterly

NAACCR

4

Implementation Guidelines/Conversion Specs



https://www.naaccr.org/implementation-guidelines/

5

AJCC Cancer Surveillance DLL

Daniel Oluwadare

No Slides

6

SEER Staging API

Nicola Schussler

NAACCR

7

SEER*RSA and SEER Staging API

Nicki Schussler

October, 2026

8

EOD – Schema adjustments

- To align with AJCC
  - New schema added for each of the new V9 diseases
    - Related 8th edition schemas will have [8th: 2018-2026] tag added
    - New V9 schemas will have [V9: 2027+] tag
  - Minor Salivary Glands [V9: 2027+] schema added
  - Colon and Rectum split for both 8th and V9
    - Colon and Rectosigmoid Junction
    - Rectum
    - Conversion is required, but no review needed

9

EOD – Schema adjustments

- Schema Redefine
  - To categorize histologies correctly in specific site-based schemas versus Soft Tissue schemas
  - Goal is to improve statistics over time by correcting how histologies are grouped
  - Michelle discussed earlier – a lot of logic, but not a lot of cases are expected

10

EOD – Calculation adjustment

- Adjustments to the following calculations
  - Breast Derived Summary Grade: now only return valid grades for behavior
  - Thyroid Derived EOD fields: Tumor Size Summary = 040 assignment for Derived EOD T was incorrect
  - Oropharynx HPV-Associated V9 Derived EOD Stage Group: Derived EOD 2018 T = TX was missing
  - Melanoma Conjunctiva Derived SS2018: EOD Primary Tumor = 750 now D instead of RE
  - Conjunctiva Derived SS2018: EOD Primary Tumor = 650 now D instead of RE

11

EOD – Dropped values

- For Breast EOD Primary Tumor [772], codes 450 and 700 were classified as obsolete last year and are being removed
  - 450 should be coded as 400; 700 should be coded as 600
- For Melanoma Conjuctiva EOD Primary Tumor [772], code 650 is obsolete and is being removed
  - 650 should be coded as 600, this also impacts Derived SS2018

12

Pediatric, Grade, Other Notes

- Pediatric Data Collection System had minor changes to notes and EOD to Pediatric conversions updates related to schema redefine
  - Plan to review the conversions in more depth for 2028
- Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck: All grade fields possible values limited to 8 as Grade doesn't apply to unknown sites.
- Pleural Mesothelioma: Schema now limited to Primary Sites C384
  - C34_ with 9050-9053 are now part of Lung for all years
  - Decision to convert any C34_ currently Pleural Mesothelioma to C384
  - Some lower EOD Primary Tumor values will also be converted
- Kidney Renal Pelvis renamed as Kidney Renal Pelvis and Ureter

13

SSDIs

SSDI changes will be discussed later in agenda

14

General

- Other minor updates were made to various fields – the notes or other descriptive data or the meaning of codes
- All changes are incorporated in the SEER Staging API and libraries
  - Other than updating the staging API that you use, there is no need for action unless conversions are specifically defined
  - Changes are documented in the change log
- Only conversions specified in the Implementation Guide need to be applied. Calculation/Derivations could be handled by reprocessing the case if that's possible in your system

15

Recent Update

- A revised version of EOD v3.4 was released recently (E-mail Oct 1, 2026)
  - Breast V9: Schema ID [3800] was corrected to be 09480
  - Cervical Lymph Nodes and Unknown Primary of Head and Neck: Schema Discriminator 1 [3926] Codes 0 and 1 and Coding Guidelines for Code 1 had references to Soft Tissue Other removed as cases would no longer be assigned to that schema
  - Soft Tissue Other: Schema Discriminator 1 [3926] was removed as it is no longer included in the schema definition

16

Cancer PathCHART Update

Alison Van Dyke

NAACCR

17

Cancer PathCHART 2027 Updates

- Sites reviewed for 2027
  - Skin
  - Hematolymphoid neoplasms
  - Endocrine organ morphologies in 5th *edition World Health Organization Classification of Tumours* made valid
- Submit questions/issues to
  - **NCICancerPathCHART@mail.nih.gov**

NAACCR

18

Cancer PathCHART 2027 Updates

- CPC SMVL released on September 17, 2026
  - **V2024C_V2025C_V2026B_V2027**
  - Excel, XML, JSON, and CSV formats
  - Read the Release Notes!
  - Change file released along with a **CPC SMVL Change File Release Notes**

https://seer.cancer.gov/cancerpathchart/products.html

NAACCR

19

Cancer PathCHART 2027 Updates

- Aligned with V27 NAACCR Edits Metafile
  - One difference
    - Ewing sarcoma (**9364/3**) of the blood (**C42.0**) is impossible – correct in current CPC SMVL
- Aligned with CPC*Search

NAACCR

20

Q&A

21

NAACCR V27 Edits Metafile

Jim Hofferkamp

22

V27 Edits

- V27 Metafile
  - Change log
- Pediatric Edits
- EDITS60
  - Email on 10/5/26 titled Action Required: NPCR Transitioning from Edits51 to Edits60 from Matthew Mayfield

Dear Software Vendors,

The National Program of Cancer Registries (NPCR) is transitioning from EDITS51 to EDITS60. **All vendors must implement EDITS60 effective with NAACCR Version 27 to remain compatible with NPCR software.** EDITS51 will be retired effective January 1, 2027.

The **NPCR EDITS60 packages are linked below** and are provided to support implementation within your software.

Key dates and requirements:

- **EDITS60 implementation deadline:** January 1, 2027.
- **EDITS51 retirement:** Effective January 1, 2027.
- **2026 data submissions:** Must continue to use the EDITS51 format. The transition to EDITS60 does not change the format requirements for 2026 submissions.

23

SSDI Working Group

EOD/SSDI Slides

24

SSDIs

- NEW SSDIs
  - Minor Salivary Tumor Location: ICD-O-3.2 site codes
    - C069 will be used for the schema; this SSDI allows specificity regarding where the gland is located
  - Rectal Tumor Location: added to Rectum V9
- Returning SSDI
  - HER2 IHC Summary [3850] and HER2 ISH Summary [3854] are being reactivated in the Breast schema. Had been required for 2018-2020

25

SSDIs

- Existing fields Recategorized as SSDIs
  - Neoadjuvant Therapy [1632], Neoadjuvant Therapy – Clinical Response [1633], Neoadjuvant Therapy – Treatment Effects [1634]
    - Coding systems revised, and Clinical Response expanded to length 2
    - Removed from schemas where Neoadjuvant doesn't apply
    - Conversion is required, but no review needed
  - Macroscopic Evaluation of Mesorectum [3950]: Rectum schemas only
- New to Schema SSDI
  - Microsatellite Instability (MSI) [3890] added to Kidney Renal Pelvis and Ureter
  - Mitotic Rate Melanoma [3893] and Ulceration [3936] added to Melanoma Conjunctiva V9

26

Revised SSDIs

- Response to Neoadjuvant Therapy [3922] in Breast: these codes were revised to align with the other Neoadjuvant therapy fields
  - Conversion is required, but no review needed
- Microsatellite Instability (MSI) [3890] in Colon, Rectum, Corpus Carcinoma and Carcinosarcoma: Code 3 was added for indeterminate and equivocal – this is for use with 2027 and later cases
- PL-D1 [1174] in Lung: codes were simplified so that only interpretations are collected
  - Conversion is required, but no review needed
- High Risk Cytogenetics [3857] in Plasma Cell Myeloma: Codes 2 and 3 were added

27

AJCC

Donna Gress

AJCC Slides

NAACCR

28

V27 Changes Sponsored by AJCC

Donna M Gress, RHIT, ODS-C

ACS AJCC American Joint Committee on Cancer
American College of Surgeons

29

ACS AJCC American Joint Committee on Cancer
American College of Surgeons

AJCC Version 9 Protocols and Data Items

30

ACS AJCC American Joint Committee on Cancer American College of Surgeons

AJCC Version 9 for 2027

- Breast
- Colon
- Rectum
- Conjunctival Carcinoma
- Conjunctival Melanoma
- Lacrimal Gland Carcinoma

© American College of Surgeons 2026. Content may not be reproduced or repurposed without the written permission of the American College of Surgeons.

31

ACS AJCC American Joint Committee on Cancer American College of Surgeons

AJCC 8th Edition or Version 9

- Determine if 8th Edition still in effect or updated to Version 9
- Table revised yearly
- For more info visit ***cancerstaging.org***
- Table on main page and Version 9 page

AJCC Current Staging System
Determine if 8th Edition still in effect or has been updated to Version 9.
Table revised yearly as additional disease sites updated. For more info visit https://cancerstaging.org

#	8th Edition Chapter Title	Edition/ Version	Version 9 Protocol Title	Current/Expected Version 9 Year
Part I: General Information on Cancer Staging and End Results Reporting				
1	Principles of Cancer Staging	8		
2	Organization of AJCC Cancer Staging Manual	8		
3	Cancer Survival Analysis	8		
4	Risk Models for Individualized Prognosis	8		
Part II: Head and Neck				
5	Staging Head and Neck Cancers	8		
6	Cervical Nodes & Unknown Primary H&N	8		
7	Oral Cavity	8		
8	Major Salivary Glands	9	Salivary Glands	2026
9	Nasopharynx	9	Nasopharynx	2025
10	HPV-Mediated (p16+) Oropharynx	9	Oropharynx (HPV-Associated)	2026
11	Oropharynx (p16-) and Hypopharynx	8		
12	Nasal Cavity and Paranasal Sinuses	8		
13	Larynx	8		
14	Mucosal Melanoma of the Head and Neck	8		
15	Cutaneous Ca of the Head and Neck	8		
Part III: Upper Gastrointestinal Tract				
16	Esophagus & Esophagogastric Junction	8		
17	Stomach	8		
18	Small Intestine	8		
Part IV: Lower Gastrointestinal Tract				
19	Appendix Carcinoma	9	Appendix Carcinoma	2023
20	Colon & Rectum	8		
21	Anus	9	Anus	2023
Part V: Hepatobiliary System				

© American College of Surgeons 2026. Content may not be reproduced or repurpose

32

ACS AJCC American Joint Committee on Cancer American College of Surgeons

Breast SSDI

- HER2 IHC Summary
  - Immunohistochemistry test
- HER2 ISH Summary
  - In situ hybridization test
  - Rationale for IHC & ISH data items discontinued in 2020
    - Reporting standardization has improved
    - Used to determine HER2-low – in clinical trials now to affect treatment
- LN Positive Axillary
  - Removed Level I & II from title to include all axillary nodes
  - Surgeons do not differentiate levels, so info can't be known
  - Need axillary count, not including other regional nodes

© American College of Surgeons 2026. Content may not be reproduced or repurposed without the written permission of the American College of Surgeons.

33

ACS AJCC American Joint Committee on Cancer American College of Surgeons

Colon and Rectum SSDI

- Rectal Tumor Location
  - Identify location of above, below, or straddles peritoneal reflection
  - Information in operative report or imaging
  - Affects treatment and risk of recurrence
- Tumor Regression Score
  - Assessment of response to neoadjuvant treatment
  - Important for patient care and prognosis
  - Plans to incorporate into AJCC stage tables in future

© American College of Surgeons 2026. Content may not be reproduced or repurposed without the written permission of the American College of Surgeons.

34

ACS AJCC American Joint Committee on Cancer American College of Surgeons

Salivary Glands SSDI

- Schema Discriminator - Identify Minor Salivary Glands
  - No ICD-O-3 code for minor salivary glands
  - Use C06.9 for site code
  - Discriminator will choose mouth or minor salivary glands
- Minor Salivary Tumor Location
  - No ICD-O codes for location of glands
  - Sites range from lips to trachea
  - Location affects treatment and prognosis

© American College of Surgeons 2026. Content may not be reproduced or repurposed without the written permission of the American College of Surgeons.

35

ACS AJCC American Joint Committee on Cancer American College of Surgeons

Conjunctival Melanoma SSDI

- Mitotic Rate Melanoma
  - Cutaneous melanoma data item now used for ophthalmic site
- Ulceration
  - Cutaneous melanoma data item now used for ophthalmic site

© American College of Surgeons 2026. Content may not be reproduced or repurposed without the written permission of the American College of Surgeons.

36

ACS AJCC American Joint Committee on Cancer American College of Surgeons

AJCC Staging – yc Requirements

- yc TNM now required on ***all*** appropriate cases
  - No longer restricted to neoadjuvant where surgery cancelled
- Necessary for no surgery planned
  - Increasing cases where systemic/radiation successful – complete response
  - Data critical for analysis of patient outcomes
- yc stage groups also used
  - Data item approved 2021
  - Needed time for data collection and analysis to determine groups
  - AJCC stage groups have prognostic meaning
  - Will be implemented on site-by-site basis, reduce burden on registrars
    - Colon and Rectum will both have yc stage groups
    - All other sites coded 88

© American College of Surgeons 2026. Content may not be reproduced or repurposed without the written permission of the American College of Surgeons.

37

ACS AJCC American Joint Committee on Cancer American College of Surgeons

Thank You

Donna M. Gress, RHIT, ODS-C

Manager, Cancer Staging and Registry Operations
AJCC and Cancer Programs

cancerstaging.org ACS Cancer Programs AJCCancer

38

NCDB

Claudia Byrd

CoC/NCDB Slides

NAACCR

39

NCDB v27 STORE Updates

NAACCR Vendor Call

Oct. 7, 2026

NATIONAL CANCER DATABASE

40

NCDB STORE v27

For cases diagnosed January 1, 2027+

New Data Items

- Cancer Status - Following First Course Tx [1769]
- Date of Cancer Status - Following First Course Tx [1768]

Revised Data Items

- AJCC TNM Post Therapy Clin (yc) staging
- Class of Case [610] codes 11&12 were removed
- Secondary Diagnosis (1-10)
- Disease Follow-up or 1st Recurrence/Progression [1880]
- Date Disease follow up/1st Recurrence/Progression [1860]
  - **New Appendix F** in STORE with Patient Follow-up Scenarios

New SSDI items

- Thoracic Nodal Stations 1-14 R/L Examined & Thoracic Nodal Stations 1-14 R/L Positive [3967- 4008]
- Rectal Tumor Location [3965]
- Salivary Gland Schema Discriminator [3926]
- Minor Salivary Gland Tumor Location [3966]
- Macroscopic Evaluation of the Mesorectum [3950

Revised SSDI items

- Treatment Effect [1634], colon & rectum Only
  - Tumor Regression Score [1634] (alternate name)
- HER2 IHC [3850]
- HER2 ISH [3854]
- Microsatellite Instability (MSI) [3890]
- PD-L1 [1174]

NATIONAL CANCER DATABASE

41

CoC New Data Items v27

New Data Items beginning for cases diagnosed January 1, 2027, and forward

- Cancer Status - Following First Course Tx [1769]
- Date of Cancer Status - Following First Course Tx [1768]

NATIONAL CANCER DATABASE

42

CoC Revised Data Items v27

CoC will collect these Revised data items for cases diagnosed 2027+

- AJCC TNM Post Therapy Clin (yc) staging for T, N, and M will be required for all cases regardless of a planned or cancelled surgery.
- Class of Case [610] codes 11&12 were removed
- Secondary Diagnosis (1-10) ICD-10-CM code restrictions lifted, include any valid ICD-10-CM codes

NATIONAL CANCER DATABASE

43

CoC Revised Data Items v27

CoC will collect these Revised data items for cases diagnosed 2027+

- Disease Follow-up or 1st Recurrence/Progression [1880]
  - Tracks longitudinal patient cancer course in coordination with item 1860
  - Reduced options from 33 - 11
- Date Disease follow up/1st Recurrence/Progression [1860]
  - Enter date with successful follow-up
  - **New Appendix F** in STORE with Patient Follow-up Scenarios

NATIONAL CANCER DATABASE

44

Coc New SSDI v27

CoC Accredited programs will collect the New SSDI items effective for cases diagnosed 2027 forward

- Thoracic Nodal Stations 1-14 R/L Examined & Thoracic Nodal Stations 1-14 R/L Positive [3967- 4008]
  - May wish to default to code 7 No surgical resection performed/No thoracic nodes examined
- Rectal Tumor Location [3965]
- Salivary Gland Schema Discriminator [3926]
- Minor Salivary Gland Tumor Location [3966]
- Macroscopic Evaluation of the Mesorectum [3950]
  - Existing data item moved to SSDI

NATIONAL CANCER DATABASE

45

Coc Revised SSDI v27

CoC Accredited programs will collect these Revised SSDI for cases diagnosed 2027+

- Treatment Effect [1634], colon & rectum Only
  - Tumor Regression Score [1634] (alternate name)
- HER2 IHC [3850] was optional, now required
- HER2 ISH [3854] was optional, now required
- Microsatellite Instability (MSI) [3890] adding new primary kidney renal pelvis and ureter schema.
  - MSI [3890] codes/code definitions changed
- PD-L1 [1174] codes/code definitions changed

NATIONAL CANCER DATABASE

46

Discontinued CoC Data Items v27

The following Data Items will **no longer** be **required** for cases diagnosed January 1,2027 or later:

- Cancer Status [1770]
- Date of Last Cancer (tumor) Status [1772]

Note: These data items will continue to be maintained by Other Standard Setters for 2027.

NATIONAL CANCER DATABASE

47

CoC User Defined Fields v27

CoC will continue to collect the user defined fields:

- Method of Detection for Breast cases [101010]
- Name-Last [2230]
- Name- Birth Surname [2232]
- Name-First [2240]
- Name- Middle [2250]
- Name-Alias [2280]

As a reminder, the name fields are only used internally at NCDB for case matching purposes. These would not be included in any reports.

NATIONAL CANCER DATABASE

48

Notable Guidance Clarifications:

1. **Sentinel Lymph Node examined/positive/date** will be required for any disease site.
   - Previously limited to Breast and Melanoma disease sites.
2. **Hematologic Transplant and Endocrine Procedures** updating terminology for codes 10,11,12,20 to include both Bone Marrow and Stem Cell Transplant.
3. Thyroid Gland [C73.9] Updated Description of **Surgical Procedure B500**
   - B500 Completion/Total thyroidectomy

NATIONAL CANCER DATABASE

49

NCDB v27 STORE Manual

- STORE v27 posted to NCDB Data Submission website:
  - https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/ncdb-data-submission/
- A descriptive summary of the STORE 2027 changes is included in the STORE Manual chapter "Summary of Changes".



NATIONAL CANCER DATABASE

50

NCDB v27 STORE Manual

Questions?

Please Contact:
NCDB@facs.org

NATIONAL CANCER DATABASE

51

NAACCR and Other Sponsors

NAACCR

52

XML Therapy Level Submission

- UDS project teams are developing a summary of proposed changes.
  - The summary will be submitted to registry vendors prior to final submission to MLTG.
  - Software vendors are strongly encouraged to submit concerns or suggestions related to the proposals.

NAACCR

53

Q&A

NAACCR

54

55